CTI Biopharma has acquired world wide rights to TOSEDOSTAT through concurrent transactions with Vernalis R&D Ltd and Chroma Therapeutics.Under terms of assets purchase agreement with Chroma Therapeutics , CTI Biopharma acquired Chroma rights,titlle , and interest in TOSEDOSTAT in exchng for USD 21.3 million in shares to Chroma Therapeutics.Also CTI Biopharma entered in to license agreement with Vernalis R&D for world wide rights to use IPR(intellectual property rights) and certain patents to develop , market and commercialize TOSEDOSTAT.